Forster steps down as Immunocore CEO

T cell receptor (TCR) therapeutics company Immunocore Ltd. (Abingdon, U.K.) said Eliot Forster stepped down as CEO. Chief Commercial Officer Andrew Hotchkiss will be interim CEO while the company searches for a replacement. Hotchkiss will also hold a board seat.

In September 2017, Immunocore received a $40 million equity investment from the Bill & Melinda Gates Foundation to develop immunotherapies for infectious diseases (see BioCentury, Sept. 22, 2017)...